Cyclacel Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Cyclacel Pharmaceuticals does not have a record of paying a dividend.

Wichtige Informationen

n/a

Dividendenausschüttung

-586.5%

Rückkaufsrendite

Gesamte Aktionärsrendite	-586.5%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Aug 07

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Apr 15

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if CYCC's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if CYCC's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

Cyclacel Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CYCC im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CYCC)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.5%
Branchendurchschnitt (Biotechs)	2.2%
Analystenprognose (CYCC) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Unable to evaluate CYCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate CYCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate CYCC's payout ratio to determine if its dividend payments are covered by earnings.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as CYCC has not reported any payouts.

Cyclacel Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Cyclacel Pharmaceuticals, Inc Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Cyclacel Pharmaceuticals Receives Subsequent Non-Compliance Notice from Nasdaq Regarding Nasdaq Listing Rule 5550(b)(1)

New major risk - Financial position

Consensus revenue estimates decrease by 11%, EPS upgraded

No longer forecast to breakeven

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as Precision Medicine for Cancer

New major risk - Negative shareholders equity

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding

Cyclacel Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Related to Shareholder's Equity

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Insufficient new directors

Cyclacel Pharmaceuticals, Inc. Announces Board Changes

Cyclacel Pharmaceuticals, Inc. Announces Executive Changes

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.525241 million.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Receives a Written Notice from the Nasdaq Stock Market

Cyclacel Pharmaceuticals, Inc. announced delayed 10-Q filing

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased to US$18.00

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Cyclacel Pharmaceuticals, Inc. Appoints Kenneth M. Ferguson as a Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$20.00

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients with Advanced Solid Tumors and Lymphomas

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Price target decreased to US$20.00

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)

Cyclacel Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients with Advanced Solid Tumors and Aggressive Lymphomas

Cyclacel Pharmaceuticals Announces Management Changes

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Cyclacel issues key business objectives for 2021

Cyclacel Pharmaceuticals Announces the Election of Brian Schwartz, M.D. to Its Board of Directors

Cyclacel Pharma inks securities purchase agreement for $7M

Cyclacel Pharmaceuticals, Inc. Appoints Karin L. Walker as Class 1 Director

Cyclacel Pharmaceuticals EPS misses by $1.74

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 11, 2020

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients with Advanced Solid Tumors At the EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen